Intel stock extends gains after report of possible U.S. government stake
Investing.com - Organogenesis (NASDAQ: ORGO) reported second quarter EPS of $-0.100, $0.05 worse than the analyst estimate of $-0.050. Revenue for the quarter came in at $149.2M versus the consensus estimate of $103.4M.
Guidance
Organogenesis sees Q3 2025 revenue of $480.000M-$510.000M versus the analyst consensus of $531.100M.
Organogenesis’s stock price closed at $4.51. It is up 47.390% in the last 3 months and up 72.140% in the last 12 months.
Organogenesis saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Organogenesis’s stock price’s past reactions to earnings here.
According to InvestingPro, Organogenesis’s Financial Health score is "good performance".
Check out Organogenesis’s recent earnings performance, and Organogenesis’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar